Aprezo 30mg Tablet
By Aprezo
Rx
10 Tablet in a Strip

Composition
Apremilast(30mg)

Manufacturer - Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.

Expires on or after
February, 2026

liver
Aprezo 30mg Tablet is considered safe for use in patients with liver disease. It is not necessary to adjust the dosage of Aprezo 30mg Tablet for individuals with liver issues. This means that patients with liver problems can generally take this medication without needing special considerations due to their liver condition. It is important to follow the prescribed dosage as instructed by your healthcare provider. Make sure to inform your doctor about any liver conditions you may have before starting Aprezo 30mg Tablet to ensure proper monitoring and management of your health.

kidney
Aprezo 30mg Tablet should be used cautiously in individuals with severe kidney disease. Dosage adjustment may be necessary, so it is important to seek advice from your healthcare provider.

alcohol
Caution is advised when consuming alcohol with Aprezo 30mg Tablet. It is important to consult your doctor before drinking alcohol while taking this medication.

driving
When taking Aprezo 30mg Tablet, it is uncertain if driving ability is affected. Avoid driving if you have symptoms that impact focus and reaction time.

pregnancy
Aprezo 30mg Tablet is considered unsafe during pregnancy due to potential harmful effects on the developing baby. Limited human studies are available, but animal studies indicate this risk. Your doctor will assess the benefits and risks before prescribing. Consult your doctor regarding its use.

breastfeeding
It is better to consult your doctor before using Aprezo 30mg Tablet.
Habit Forming | No |
Chemical Class | Isoindole Derivative |
Therapeutic Class | PAIN ANALGESICS |
Action Class | - |
₹325
Inclusive of all taxes
Content verified by

Dr. Gowri Kulkarni
MBBS - General Medicine, DNB - Psychiatry, MRCGP [INT] Family Medicine, BSIC (BACP)
Last update on 01-Oct-2024